VJHemOnc Podcast

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Laurie Sehn, MD, BC Cancer Agency, Vancouver, Canada, Carmelo Carlo Stella, MD, PhD, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan Italy, and David Straus, MD, Memorial Sloan Kettering Cancer Center, New York, NY, share some insights into novel therapies in non-Hodgkin lymphoma (NHL), drawing focus on the role of antibody-drug conjugates (ADCs). The experts discuss updates on the use of several ADCs, including brentuximab vedotin, loncastuximab tesirine, polatuzumab vedotin, and camidanlumab tesirine, and where these agents fit in the treatment landscape.

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, and Carsten Müller-Tidow, MD, University Hospital Heidelberg, Heidelberg, Germany, discuss mechanisms of resistance to targeted therapies in AML, and the role of epigenetics. 

Chronic lymphocytic leukemia (CLL) remains a challenging hematological malignancy to treat, and genomic testing has become increasingly important in this disease. Several genomic tests are commonly carried out prior to initiating treatment, including testing for TP53 aberrations, IgHV mutational status, and more. 

In this podcast, you will hear from Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, Florence Cymbalista, MD, Hôpital Avicenne, Bobigny, France, and Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, who discuss the importance of genomic testing in CLL and how this impacts treatment decisions.

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children's National Health System, Washington, DC, Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA, Barbara Savoldo, MD, PhD, UNC School of Medicine, Chapel Hill, NC, and Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, discuss the latest updates in T-cell therapies for the treatment of NHL, commenting on real-world data on CD19-directed CAR-Ts, and exploring the potential of other T-cell therapies including CD30, CD20, and CD5-directed CAR-Ts in T-cell lymphomas. 

The treatment landscape of chronic lymphocytic leukemia (CLL) has transformed over the years with the increased use of Bruton's tyrosine kinase (BTK) inhibitors, which have demonstrated promising results in several clinical trials. 

In this podcast, leading experts Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Catherine Coombs, MD, UC Irvine Health, Orange, CA, discuss key updates in CLL, including the changing role of chemotherapy in the era of novel agents, the promise of next-generation BTK inhibitors, and more. This discussion took place at the 10th Annual Meeting of the Society of Hematologic Oncology (SOHO), which was held in Houston, TX, from September 28-October 1.

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, you will hear from Bijal Shah, MD, H. Lee Moffitt Cancer Center, Tampa, FL, Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Nicolas Boissel, MD, PhD, Saint-Louis Hospital, Paris, France, who discuss the evolving treatment landscape in ALL, debating the role of immunotherapies, including antibody-drug conjugates (ADCs) and CAR-T cells.

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.

This podcast episode focuses on the optimal management of relapsed/refractory (R/R) follicular lymphoma (FL), where you will hear from Laura Pasqualucci, MD, Columbia University Irving Medical Center, New York, NY, Jessica Okosun, MA, MB BChir, MRCP, FRCPath, PhD, Barts Cancer Institute, Queen Mary University of London, London, UK, and David Qualls, MD, Memorial Sloan Kettering Cancer Center, New York, NY. The experts debate on how to best treat, combine, and sequence therapies in R/R FL, and further comment on the role of epigenetic alterations in this disease. 

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discuss novel targets and combinations in AML, treatment approaches for patients with TP53-mutated disease, and more. 

The 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) was held in Houston, TX, from September 28-October 1, and brought together leading experts to discuss recent advances in hematological malignancies.

In this podcast, you will hear from experts Jorge Cortes, MD, Augusta University, Augusta, GA, and Mhairi Copland, MB ChB, PhD, University of Glasgow, Glasgow, UK, who discuss the latest in chronic myeloid leukemia (CML), including treatment strategies for patients with multiple refractory disease, and novel agents in the field. The experts also comment on clinical trial updates, including data from the OPTIC trial (NCT02467270) and the ASCEMBL trial (NCT03106779).

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.

The second session from iwNHL focused on the role of the tumor immune microenvironment in lymphoma. In this podcast, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Center, Toronto, Canada, and Gaël Roué, PhD, Josep Carreras Leukemia Research Institute, Barcelona, Spain, discuss the importance of understanding the tumor immune microenvironment in NHL. The experts outline strategies to engage the innate and adaptive anti-tumor immune response, and explain how this can be used to enhance the efficacy of immune therapies.